Mandate

Vinge advises Industrifonden in connection with its investment in Agteria Biotech

Vinge has advised Industrifonden in connection with their participation as lead investor, together with AgriZeroNZ, in the seed financing round in Agteria Biotech AB.

Agteria Biotech AB is a Swedish start-up dedicated to reducing 1% of the global greenhouse gas emissions through its patent-pending molecule that significantly reduces methane emissions from cattle. The new funding will enable the company to advance towards regulatory approval for its methane-reducing molecule, focusing on safety studies for animals, consumers, and the environment.

The Vinge team consisted primarily of JJohan Larsson, Maria Dahlin Kolvik, Ian Linde (M&A), Åsa Hellstadius, Rebecka Målquist (IP), Simon Söderholm and Agnes Pigg (Employment).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026